Authors : M. Prashanth Kumar Reddy; Pamu Vara Laxmi; V.Keerthi Bhavana

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/53mcjjrx

Scribd : https://tinyurl.com/3hr8fsyc

DOI : https://doi.org/10.38124/ijisrt/25jul1108

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : The illness now referred to as Angelman syndrome (AS), originally termed the "Puppet Children," was first recorded in 1965 by a British physician named Harry Angelman. Angelman observed that three children with cognitive disability had certain traits: a positive disposition towards people, uncoordinated or spasmodic motions, and limited or absent verbal communication abilities. In 1987, Ellen Magenis discovered two children with notable deletions on chromosome 15. This genetic abnormality was linked to a phenotype characterized by severe ataxia, seizures, and episodes of prolonged and spontaneous laughter. Due to its exclusive imprinting in the brain, the expression of the UBE3A gene is limited to the neurological system, leading to most of the manifestations of Angelman syndrome (AS) being confined to this system. Patients who are suspected of having Angelman syndrome are initially assessed by clinical evaluation using DNA methylation assays, specifically targeting the differentially methylated SNRPN promoter/exon 1 region. The current approach to managing Angelman syndrome is mostly focused on addressing symptoms; however, there are promising gene- based medicines under development. The primary emphasis of medications used in the treatment of epilepsy in Angelman syndrome is on moderate motor or akinetic seizures. Valproate, clonazepam, topiramate, lamotrigine, and levetiracetam have demonstrated potential, whilst carbamazepine, phenobarbital, oxcarbazepine, and vigabatrin have shown limited potential.

Keywords : Angelman Syndrome, Chromosome 15, Puppet Children, Haploinsufficiency Syndrome, UBE3A Gene.

References :

1. Hart, H. (2003). Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet, 50(8), 87–95.
2. Jana, N. R. (2012). Understanding the pathogenesis of Angelman syndrome through animal models. Neural Plasticity, 2012, 1–10.
3. Van Buggenhout, G., & Fryns, J.-P. (2009). Angelman syndrome (AS, MIM 105830). European Journal of Human Genetics: EJHG, 17(11), 1367–1373.
4. Fiumara, A., Pittalà, A., Cocuzza, M., & Sorge, G. (2010). Epilepsy in patients with Angelman syndrome. Italian Journal of Pediatrics, 36(1), 31.
5. Mishra, A., Godavarthi, S. K., & Jana, N. R. (2009). UBE3A/E6-AP regulates cell proliferation by promoting proteasomal degradation of p27. Neurobiology of Disease, 36(1), 26–34.
6. Kühnle, S., Mothes, B., Matentzoglu, K., & Scheffner, M. (2013). Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein Arc. Proceedings of the National Academy of Sciences of the United States of America, 110(22), 8888–8893.
7. Williams, C. A. (2010). The behavioral phenotype of the Angelman syndrome. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 154C(4), 432–437.
8. Tan, W.-H., Bird, L. M., Thibert, R. L., & Williams, C. A. (2014). If not Angelman, what is it? a review of Angelman‐like syndromes. American Journal of Medical Genetics. Part A, 164(4), 975–992.

9. Keute, M., Miller, M. T., Krishnan, M. L., Sadhwani, A., Chamberlain, S., Thibert, R. L., Tan, W.-H., Bird, L. M., & Hipp, J. F. (2021). Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Molecular Psychiatry, 26(7), 3625–3633.
10. Maranga, C., Fernandes, T. G., Bekman, E., & da Rocha, S. T. (2020). Angelman syndrome: a journey through the brain. The FEBS Journal, 287(11), 2154–2175.
11. Sell, G. L., Xin, W., Cook, E. K., Zbinden, M. A., Schaffer, T. B., O’Meally, R. N., Cole, R. N., & Margolis, S. S. (2021). Deleting a UBE3A substrate rescues impaired hippocampal physiology and learning in Angelman syndrome mice. Scientific Reports, 11(1), 19414.
12. Huibregtse, J. M., Scheffner, M., & Howley, P. M. (1993). Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Molecular and Cellular Biology, 13(2), 775–784.
13. Buiting, K., Williams, C., & Horsthemke, B. (2016). Angelman syndrome — insights into a rare neurogenetic disorder. Nature Reviews. Neurology, 12(10), 584–593.
14. Bonello, D., Camilleri, F., & Calleja-Agius, J. (2017). Angelman syndrome: Identification and management. Neonatal Network The Journal of Neonatal Nursing, 36(3), 142–151.
15. Driscoll, C.-S. J., Waters, D. J., Webb, M. F., Andrews, T., Malcolm, T., Pembrey, S., & Nicholls, M. E. (1993). Difference in methylation patterns within the D15S9 region of chromosome 15qll-13 in first cousins With Angelman syndrome and Prader-Willi syndrome. Am J Med Genet, 47, 683–686.
16. Guo, C. C., Tan, R., Hodges, J. R., Hu, X., Sami, S., & Hornberger, M. (2016). Network-selective vulnerability of the human cerebellum to Alzheimer’s disease and frontotemporal dementia. Brain: A Journal of Neurology, 139(5), 1527–1538.
17. Bird, L. M., Tan, W.-H., Bacino, C. A., Peters, S. U., Skinner, S. A., Anselm, I., Barbieri-Welge, R., Bauer-Carlin, A., Gentile, J. K., Glaze, D. G., Horowitz, L. T., Mohan, K. N., Nespeca, M. P., Sahoo, T., Sarco, D., Waisbren, S. E., & Beaudet, A. L. (2011). A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. American Journal of Medical Genetics. Part A, 155A(12), 2956–2963.
18. Grieco, J. C., Ciarlone, S. L., Gieron-Korthals, M., Schoenberg, M. R., Smith, A. G., Philpot, R. M., Heussler, H. S., Banko, J. L., & Weeber, E. J. (2014). An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurology, 14(1), 232.
19. Whitfield, A. C., Moore, B. T., & Daniels, R. N. (2014). Classics in chemical neuroscience: levodopa. ACS Chemical Neuroscience, 5(12), 1192–1197.

20. Sosanya, N. M., Cacheaux, L. P., Workman, E. R., Niere, F., Perrone-Bizzozero, N. I., & Raab-Graham, K. F. (2015). Mammalian target of rapamycin (mTOR) tagging promotes dendritic branch variability through the capture of Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) mRNAs by the RNA-binding protein HuD. The Journal of Biological Chemistry, 290(26), 16357–16371.
21. Stoodley, C. J. (2016). The cerebellum and neurodevelopmental disorders. Cerebellum (London, England), 15(1), 34–37.